1. Dihydroquercetin regulates HIF-1α/AKT/NR2B signalling to improve impaired brain function in rats with metabolic syndrome
- Author
-
Yang Fu, PeiPei Yuan, Mengnan Zeng, Qi Zhang, Ying Hou, Liyuan Gao, Yaxin Wei, Yajuan Zheng, Weisheng Feng, and Xiaoke Zheng
- Subjects
Dihydroquercetin ,Hypertension ,Brain ,Metabolic syndrome ,HIF-1α/AKT/NR2B ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Dihydroquercetin (DHQ) is commonly used as a dietary additive, but its activity in improving brain injury with metabolic syndrome (MS) remains known. In present study, the MS rat model was induced using 10 % fructose water. The apoptosis rate of primary brain cells was detected. The HIF-1α/AKT/NR2B signalling pathway, levels of KEAP1/NRF2, HO-1 and NQO-1 were detected. In vitro experiments were performed using H2O2-stimulated PC-12 cells. The effect of DHQ on rates of cell survival and apoptosis were detected. After silencing HIF-1α, we further elucidate the mechanism of action of DHQ. The results indicated that DHQ reduced the hyperactivity and inhibited oxidative stress via increasing the levels of HIF-1α/AKT/NR2B signalling pathway, whereas regulated KEAP1/NRF2 pathway. In vitro experiments showed that the HIF-1α plays an important role in this process. Overall, DHQ may improve impaired brain function in rats with metabolic syndrome by regulating the HIF-1α/AKT/NR2B signalling pathway.
- Published
- 2024
- Full Text
- View/download PDF